INTRODUCTION
============

Since late 1990s, the treatment for varicose veins has undergone dramatic changes with the introduction of percutaneous endovenous ablation techniques, including endovenous laser treatment, radiofrequency ablation (RFA), foam sclerotherapy and nonthermal nontumescent treatment such as mechanochemical ablation (Clarivein, South Jordan, UT, USA) and Cyanoacrylate glue (VenaSeal, Medtronic, Minneapolis, MN, USA) \[[@B1][@B2][@B3][@B4][@B5]\]. In randomized controlled trials, endovenous therapy showed better results than high ligation and stripping in terms of pain relief, rapid recovery and improved quality of life (QoL) \[[@B6]\]. Between the 2 thermal endovenous solutions, RFA was associated with less periprocedural pain, requirement for analgesics, and bruising \[[@B7]\].

The RFA technique involves the induction of endofibrosis in the saphenous vein walls by applying heat from the intravenous catheter. RFA of great saphenous veins (GSVs) larger than 12 mm in diameter has been controversial because of an increased risk of incomplete obliteration and target vein phlebitis \[[@B8][@B9]\]. After the current second generation ClosureFast (Venefit, Covidien, Mansfield, MA, USA) catheter was introduced in 2007, with routine use of tumescent anesthesia, the 12-mm size limitation is no longer considered issue \[[@B10][@B11][@B12]\]. However, there is limited data on both the efficacy and safety of RFA for saphenous veins with a large diameter.

This study aimed to determine whether large-diameter (\>12 mm) GSV affected closure rate, complications, and clinical and QoL improvement following RFA procedure.

METHODS
=======

Patients
--------

This was a retrospective single-center study including patients who underwent RFA due to symptomatic varicose vein with saphenofemoral junction (SFJ) reflux from January 2012 to September 2016. Patients who underwent reoperation and small saphenous vein ablation simultaneously were excluded from the study. Data were collected by medical record review. This study was approved by the Boramae Medical Center Institutional Review Board (approval number: 20-2018-89) with waiver of informed consent because the research would pose no more than minimal risk to the patients and have no adverse effects on the subjects. This study was carried out in accordance with the ethical guidelines of the 1975 Declaration of Helsinki.

Preoperative evaluation
-----------------------

Clinical severity data were collected using Clinical, Etiology, Anatomy and Pathophysiology (CEAP) classification. Data on symptoms and QoL were collected using the Venous Clinical Severity Score (VCSS) and the Aberdeen Varicose Vein Symptom Severity Score (AVSS) \[[@B13][@B14]\]. Duplex scan was performed to measure a maximum diameter of GSV. This diameter was recorded 3 cm below the SFJ in the upright position, according to the International Union of Phlebology consensus document on duplex ultrasound \[[@B15]\]. Thus, patients were divided into 2 groups according to their vein diameter (group A ≤12 mm, group B \>12 mm).

RFA procedures
--------------

All procedures were performed in an operating room under local anesthesia or monitored anesthesia care. Patients were placed in the supine position and ultrasound-guided puncture of the GSV was done at the level of the knee using a micropuncture needle. Using a flexible guidewire, a 7F sheath was inserted, and the ClosureFast RFA catheter was advanced into the GSV through the sheath. The tip of the catheter was positioned 2.0 to 2.5 cm distal to the SFJ, and duplex ultrasound was used to confirm the position of the tip of the catheter. Tumescent anesthesia was injected into the tissues surround the GSV with a dose of 10 mL per 1 cm length. The heating element was activated with radiofrequency energy to 120℃ for 20 seconds. Energy was delivered by withdrawing the catheter at an interval of 6.5 cm. After procedures, all patients used a compression stocking for 2 weeks and received nonsteroidal anti-inflammatory drugs (NSAIDs) for a week.

Outcomes
--------

Follow-up ultrasound evaluation was performed between 3 to 5 days, and at 1, 3, 6, and 12 months postoperatively. Complete closure of the saphenous vein was defined as noncompressibility and/or absence of flow signal along the entire treated saphenous vein segment on duplex ultrasound with no discrete segments of patency exceeding 5 cm from the SFJ \[[@B16]\]. Efficacy was evaluated with the VCSS and the AVSS improvement as well as closure rate. Clinical evaluation was performed 1 month and again at 3, 6, and 12 months following the procedure. Safety was defined based on postoperative complications. Complications after RFA were classified and compared according to guideline from Society of Interventional Radiology Standards of Practice Committee \[[@B17]\]. Endovenous heat induced thrombosis (EHIT) was classified according to the degree of extension of thrombus into the deep venous system \[[@B18]\]. Phlebitis was defined as redness, swelling and pain in the treated area and induration was defined as redness without other inflammatory sign.

Statistical analysis
--------------------

Continuous variables are presented as mean ± standard deviation and were compared with the Student t-test and repeated measures analysis of variance. Chi-square tests were used to compare categorical variables. The Kaplan-Meier method and log-rank tests were used to calculate and compare the closure rates between groups. Statistical significance was determined when the P-value was less than 0.05. Statistical analysis was performed using the IBM SPSS Statistics ver. 19.0 (IBM Co., Armonk, NY, USA).

RESULTS
=======

Baseline characteristics
------------------------

During the study period, 493 consecutive patients with 722 limbs were treated with RFA for incompetent GSV. There were 663 veins in group A with a mean diameter of 6.00 ± 1.74 mm (median, 5.73; range, 3.04--9.88 mm). Group B consisted of 59 veins with a mean GSV diameter of 13.17 ± 1.28 mm (median, 12.70; range, 12.10--17.20 mm). The mean age was 56.0 ± 12.7 years in group A and 56.0 ± 10.4 years in group B. No significant differences were observed in follow-up duration (P = 0.357) and percentage of patients with the C2 in CEAP clinical classification (81.0% and 86.4%, P = 0.121) ([Table 1](#T1){ref-type="table"}). Concomitant ambulatory phlebectomy was performed in 605 patients (91.3%) in group A and 59 patients (100%) in group B.

Vein closure rate
-----------------

Successful closure of the treated GSV was achieved in all patients, and was evaluated with a duplex scan at the end of the procedure. Vein closure rates evaluated with duplex scan in group A were 100%, 99.7%, and 98.9% at 1 month, 6 months, and 12 months, respectively. Vein closure rate in group B was 100% for each follow-up ([Fig. 1](#F1){ref-type="fig"}). There were no statistically significant differences in vein closure rate at 12 months between the 2 groups (P = 0.428).

Incidence of complications
--------------------------

Postoperative complications were found in 132 patients (19.9%) in group A and 8 patients (13.6%) in group B ([Table 2](#T2){ref-type="table"}). The most common complication was paresthesia, which occurred in 39 cases (5.4%). Paresthesia disappeared in most cases without additional treatments. There was no statistically significant difference in each complication, including phlebitis and EHIT between the 2 groups. Most patients with phlebitis only required the medications for a few days without the need for hospitalization. No patient in group B experienced severe phlebitis. Two patients (0.3%) from group A and 1 (1.7%) from group B experienced EHIT class 3. They received anticoagulation therapy and EHIT resolved completely.

Improvements of VCSS and AVSS
-----------------------------

Mean VCSS improved from 3.52 ± 1.41 at baseline to 1.01 ± 0.92 at 1 month and to 0.07 ± 0.30 at 12 months in group A. In group B, the mean VCSS score decreased from 3.88 ± 1.52 at preoperative survey to 1.07 ± 0.69 at 1 month and to 0.06 ± 0.35 at 12 months. Both groups showed marked improvement of symptoms at 1, 3, 6, and 12 months postoperatively, with no significant differences (all P \> 0.05) ([Fig. 2](#F2){ref-type="fig"}).

The AVSS, an index of QoL, was measured preoperatively and at 1, 3, 6, and 12 months after treatment. Mean AVSS improved from 29.33 ± 8.07 at baseline to 8.66 ± 5.12 at 1 month and to 0.76 ± 2.51 at 12 months in group A. In group B, the mean AVSS decreased from 31.07 ± 8.54 at baseline to 9.93 ± 4.53 at 1 month and to 0.70 ± 2.69 at 12 months. The improvements in the AVSS from the preoperative period to follow-ups at 1, 3, 6, and 12 months were not significantly different between the 2 groups (all P \> 0.05) ([Fig. 3](#F3){ref-type="fig"}).

DISCUSSION
==========

The diameter of the saphenous vein was one of the limiting criteria for RFA use previously. The first-generation catheter, ClosurePlus catheter, for RFA consisted of extendable prongs to contact the saphenous vein wall. In the completely deployed state, the larger one, among the available devices, had a dimeter of 12 mm \[[@B10]\]. Therefore, it was considered that the maximum vein diameter for RFA should be 12 mm \[[@B10]\]. The second-generation RFA-device, ClosureFast catheter, was launched in 2006. With the introduction of this RFA device, its use in GSV larger than 12 mm is no longer considered a contraindication.

There are several reports on the outcomes of RFA in large diameter GSV. Gloviczki et al. \[[@B19]\] suggested saphenous vein diameters larger than 15 mm as a limiting factor for RFA because of an increased risk of incomplete obliteration and target vein phlebitis. However, Calcagno et al. \[[@B10]\] firstly evaluated the effect of saphenous vein diameter on closure rate and reported that a saphenous vein diameter larger than 12 mm had no effect on closure rate with the ClosureFast catheter. In the study by Proebstle et al. \[[@B20]\], even saphenous veins as large as 18 mm in diameter were treated by RFA with ClosureFast catheter with an overall closure rate of 99.6%.

Our results showed that closure rates exceed 98% at 12 months regardless of vein diameter. We reported excellent results comparative with those of initial studies with second-generation catheters \[[@B20][@B21]\]. Good results were achieved because relatively large number of patients was followed-up and the study was performed after the initial period of second generation of RFA device. Additionally, we showed results with longer-term follow-up than that in the previous study on large diameter veins \[[@B10]\]. We collected the data on the improvements on the VCSS and the AVSS. There were few reports which analyzed these indexes in association with GSV diameter before. We evaluated clinical improvement after RFA using both the VCSS and the AVSS, unlike to a recent study on RFA in large diameter veins \[[@B12]\]. With this, we showed comprehensive results of RFA in larger diameter GSV.

Major complications after RFA ablation were uncommon. The overall major complication rate based on pooled events in RFA cohort studies from Medical Advisory Secretariat evidence review was 2.9% \[[@B22]\]. Deep vein thrombosis (DVT) is the most frequently mentioned major adverse event. In a study with 2,470 cases with RFA, the incidences of DVT and EHIT were 0.7% and 0.4%, respectively \[[@B23]\]. In our series, the incidence of EHIT was comparable to the previous report. Moreover, there was no difference between the groups as well. Larger diameter of GSV did not increase the risk of EHIT in our study.

Minor complications, such as paresthesia and hematoma, were relatively common. However, it was not clear to what extent these complications were due to either the primary RFA therapy or concomitant procedures such as phlebectomy. In our cases, ambulatory phlebectomy was performed on most of the cases (664 limbs, 92.0%). In the previous studies, paresthesia was reported as the most common among the minor complications with an incidence of 3.2% to 12.3% \[[@B20][@B24][@B25]\]. In our results, the paresthesia was reported 5.7% and 1.7% in each group without significant differences. In addition, phlebitis occurred similarly in both groups with low incidence. The vein diameter did not influence the incidence of paresthesia or phlebitis.

Our study had several limitations. First, it was a retrospective study with a relatively short follow-up duration. Data from a longer follow-up duration can provide more conclusive data. Second, all the patients were prescribed NSAIDs. The medication compliance could be different between the groups, which might influence the incidence of phlebitis or pain. Third, as mentioned earlier, concomitantly performed phlebectomy could affect the incidence of complications, such as phlebitis, pain, hyperpigmentation, and paresthesia.

In conclusion, for large-diameter veins, with diameters larger than 12 mm, RFA showed comparable outcomes for closure rate, complications, and clinical and QoL improvement. The large diameter of GSV is not a hindrance or contraindication for RFA.
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###### Demographic characteristics of 722 limbs
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Values are presented as mean ± standard deviation or number (%).

Group A, vein diameter ≤ 12 mm; group B, vein diameter \> 12 mm; GSV, great saphenous vein; CEAP, Clinical, Etiology, Anatomy, and pathophysiology.

###### Incidence of complications
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Values are presented as number of limbs (%).

Group A, vein diameter ≤ 12 mm; group B, vein diameter \> 12 mm; EHIT, endovenous heat-induced thrombosis.
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